{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:56:44Z","timestamp":1781650604445,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korean government","award":["HI22C0360"],"award-info":[{"award-number":["HI22C0360"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47884-x","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T16:26:55Z","timestamp":1776529615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization"],"prefix":"10.1038","volume":"16","author":[{"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukmook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"6","key":"47884_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/0008-5472.CAN-16-1647","volume":"77","author":"S Lim","year":"2017","unstructured":"Lim, S. et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res. 77 (6), 1245\u20131249 (2017).","journal-title":"Cancer Res."},{"key":"47884_CR2","doi-asserted-by":"crossref","unstructured":"Aktar, N. et al. Understanding of immune escape mechanisms and advances in cancer immunotherapy. J. Oncol. 2022, 8901326 (2022).","DOI":"10.1155\/2022\/8901326"},{"key":"47884_CR3","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. 13, 964442 (2022).","journal-title":"Front. Immunol."},{"issue":"8","key":"47884_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.5483\/BMBRep.2021.54.8.054","volume":"54","author":"J Moon","year":"2021","unstructured":"Moon, J., Oh, Y. M. & Ha, S. J. Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications. BMB Rep. 54 (8), 403\u2013412 (2021).","journal-title":"BMB Rep."},{"key":"47884_CR5","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"JW Cui","year":"2024","unstructured":"Cui, J. W. et al. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed. Pharmacother. 171, 116203 (2024).","journal-title":"Biomed. Pharmacother"},{"issue":"3","key":"47884_CR6","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D. & Li, L. PD-1\/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10 (3), 727\u2013742 (2020).","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"47884_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank, C., Gajewski, T. F. & Mackensen, A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol. Immunother. 54 (4), 307\u2013314 (2005).","journal-title":"Cancer Immunol. Immunother"},{"issue":"3","key":"47884_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/19420862.2015.1136043","volume":"8","author":"R Deng","year":"2016","unstructured":"Deng, R. et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs 8 (3), 593\u2013603 (2016).","journal-title":"mAbs"},{"issue":"9","key":"47884_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart, R. et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol. Res. 3 (9), 1052\u20131062 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"47884_CR10","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/cti.2016.27","volume":"5","author":"I Grenga","year":"2016","unstructured":"Grenga, I., Donahue, R. N., Lepone, L. M., Richards, J. & Schlom, J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin. Transl Immunol. 5 (5), e83 (2016).","journal-title":"Clin. Transl Immunol."},{"issue":"10","key":"47884_CR11","doi-asserted-by":"publisher","first-page":"e007637","DOI":"10.1136\/jitc-2023-007637","volume":"11","author":"P Clingan","year":"2023","unstructured":"Clingan, P. et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J. Immunother Cancer. 11 (10), e007637 (2023).","journal-title":"J. Immunother Cancer"},{"issue":"1","key":"47884_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother Cancer. 7 (1), 278 (2019).","journal-title":"J. Immunother Cancer"},{"issue":"5","key":"47884_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann. Oncol. 31 (5), 599\u2013608 (2020).","journal-title":"Ann. Oncol."},{"key":"47884_CR14","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.neo.2023.100884","volume":"38","author":"T Kolb","year":"2023","unstructured":"Kolb, T., Benckendorff, J., M\u00f6ller, P., Barth, T. F. E. & Marienfeld, R. B. Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. Neoplasia 38, 100884 (2023).","journal-title":"Neoplasia"},{"issue":"7","key":"47884_CR15","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis, M. E., Andrews, L. P. & Vignali, D. A. Inhibitory receptors as targets for cancer immunotherapy. Eur. J. Immunol. 45 (7), 1892\u20131905 (2015).","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"47884_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal. Transduct. Target. Ther. 10 (1), 227 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"47884_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12032-025-02822-1","volume":"42","author":"MR Zamani","year":"2025","unstructured":"Zamani, M. R. & \u0160\u00e1cha, P. Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies? Med. Oncol. 42 (7), 273 (2025).","journal-title":"Med. Oncol."},{"issue":"2","key":"47884_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","volume":"4","author":"RE Kontermann","year":"2012","unstructured":"Kontermann, R. E. Dual targeting strategies with bispecific antibodies. mAbs 4 (2), 182\u2013197 (2012).","journal-title":"MAbs"},{"key":"47884_CR19","doi-asserted-by":"publisher","first-page":"105037","DOI":"10.1016\/j.critrevonc.2025.105037","volume":"217","author":"OJ Okpasuo","year":"2025","unstructured":"Okpasuo, O. J. et al. The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond. Crit. Rev. Oncol. Hematol. 217, 105037 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"47884_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","volume":"23","author":"H Li","year":"2025","unstructured":"Li, H. et al. Nanobodies and their derivatives: pioneering the future of cancer immunotherapy. Cell. Commun. Signal. 23 (1), 271 (2025).","journal-title":"Cell. Commun. Signal."},{"key":"47884_CR21","doi-asserted-by":"publisher","first-page":"2516676","DOI":"10.1080\/19420862.2025.2516676","volume":"17","author":"MF Erasmus","year":"2025","unstructured":"Erasmus, M. F. et al. Developing drug-like single-domain antibodies (VHH) from in vitro libraries. mAbs 17, 2516676 (2025).","journal-title":"mAbs"},{"key":"47884_CR22","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"BK Jin","year":"2023","unstructured":"Jin, B. K., Odongo, S., Radwanska, M. & Magez, S. NANOBODIES\u00ae: A review of diagnostic and therapeutic applications. Int. J. Mol. Sci. 24, 5994 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"47884_CR23","doi-asserted-by":"publisher","first-page":"2583210","DOI":"10.1080\/19420862.2025.2583210","volume":"17","author":"A Evers","year":"2025","unstructured":"Evers, A., Guarnera, E., Pekar, L. & Zielonka, S. From discovery to the clinic: structural insights, engineering options, clinical, and \u2018next wave\u2019 applications of camelid-derived single-domain antibodies. mAbs 17, 2583210 (2025).","journal-title":"mAbs"},{"issue":"9","key":"47884_CR24","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.3390\/ijms25094791","volume":"25","author":"HE Lee","year":"2024","unstructured":"Lee, H. E. et al. Development, high-throughput profiling, and biopanning of a large phage display single-domain antibody library. Int. J. Mol. Sci. 25 (9), 4791 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"47884_CR25","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee, D., Cho, M., Kim, E., Seo, Y. & Cha, J. H. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol. Ther. 32 (12), 4235\u20134255 (2024).","journal-title":"Mol. Ther."},{"key":"47884_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3390\/ijms18061331","volume":"18","author":"M \u0160mahel","year":"2017","unstructured":"\u0160mahel, M. PD-1\/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int. J. Mol. Sci. 18, 1331 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"47884_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"JY Sun","year":"2020","unstructured":"Sun, J. Y. et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark. Res. 8, 35 (2020).","journal-title":"Biomark. Res."},{"issue":"1","key":"47884_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13036-025-00577-x","volume":"19","author":"JY Ha","year":"2025","unstructured":"Ha, J. Y. et al. Directed evolution-driven reprogramming of PD-L1 for compact and tunable checkpoint modulation. J. Biol. Eng. 19 (1), 108 (2025).","journal-title":"J. Biol. Eng."},{"issue":"23","key":"47884_CR29","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3390\/cancers17233803","volume":"17","author":"B Pell","year":"2025","unstructured":"Pell, B. et al. Dynamic PD-L1 regulation shapes tumor immune escape and response to immunotherapy. Cancers 17 (23), 3803 (2025).","journal-title":"Cancers"},{"key":"47884_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin, S. et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal. Transduct. Target. Ther. 7, 39 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"8","key":"47884_CR31","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1021\/acs.jmedchem.3c02143","volume":"67","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Yuan, L., Liao, X., Guo, X. & Chen, J. Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1\/PD-L1 pathway. J. Med. Chem. 67 (8), 6027\u20136043 (2024).","journal-title":"J. Med. Chem."},{"issue":"3","key":"47884_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48 (3), 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"47884_CR33","doi-asserted-by":"publisher","first-page":"216318","DOI":"10.1016\/j.canlet.2023.216318","volume":"569","author":"Q Lin","year":"2023","unstructured":"Lin, Q., Wang, X. & Hu, Y. The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells. Cancer Lett. 569, 216318 (2023).","journal-title":"Cancer Lett."},{"key":"47884_CR34","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.addr.2023.114726","volume":"195","author":"YJ Kim","year":"2023","unstructured":"Kim, Y. J., Sang, J., Xiang, Z., Shen, Y., Shi, Y. & Z., & Nanobodies: robust miniprotein binders in biomedicine. Adv. Drug Deliv Rev. 195, 114726 (2023).","journal-title":"Adv. Drug Deliv Rev."},{"issue":"1","key":"47884_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer. 18 (1), 155 (2019).","journal-title":"Mol. Cancer"},{"issue":"1","key":"47884_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L., Li, Y., Tan, J., Xu, L. & Li, Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16 (1), 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"47884_CR37","doi-asserted-by":"publisher","first-page":"681320","DOI":"10.3389\/fphar.2021.681320","volume":"12","author":"JB Lee","year":"2021","unstructured":"Lee, J. B., Ha, S. J. & Kim, H. R. Clinical insights into novel immune checkpoint inhibitors. Front. Pharmacol. 12, 681320 (2021).","journal-title":"Front. Pharmacol."},{"key":"47884_CR38","doi-asserted-by":"publisher","first-page":"972046","DOI":"10.3389\/fphar.2022.972046","volume":"13","author":"A Zanello","year":"2022","unstructured":"Zanello, A., Bortolotti, M., Maiello, S., Bolognesi, A. & Polito, L. Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering? Front. Pharmacol. 13, 972046 (2022).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"47884_CR39","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","volume":"11","author":"EY Lemma","year":"2023","unstructured":"Lemma, E. Y., Letian, A., Altorki, N. K. & McGraw, T. E. Regulation of PD-L1 trafficking from synthesis to degradation. Cancer Immunol. Res. 11 (7), 866\u2013874 (2023).","journal-title":"Cancer Immunol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47884-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:22:04Z","timestamp":1781648524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47884-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47884-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18095"}}